Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abnormal laboratory test values during ceftriaxone therapy.

M Oakes, H MacDonald, D Wilson

    The American Journal of Medicine
    |October 19, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Suicidal ideation in a random community sample: attributable risk due to depression and psychosocial and traumatic events.

    The Australian and New Zealand journal of psychiatry·2001
    Same author

    Index of suspicion. Case 3. Diagnosis: septic arthritis.

    Pediatrics in review·2001
    Same author

    The European Society of Gastrointestinal Endoscopy (ESGE): check list for the purchase of washer-disinfectors for flexible endoscopes. ESGE Guideline Committee.

    Endoscopy·2000
    Same author

    Why nurses need to advocate for Medicare by opposing contracting out.

    Alberta RN·2000
    Same author

    Glioblastoma induction after radiosurgery for meningioma.

    Lancet (London, England)·2000
    Same author

    The low prevalence of shiga-toxin production among sorbitol non-fermenting Escherichia coli urinary tract isolates does not warrant routine screening.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
    Same journal

    GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

    The American journal of medicine·2026
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric Panniculitis.

    The American journal of medicine·2026
    Same journal

    Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

    The American journal of medicine·2026
    See all related articles

    Ceftriaxone demonstrates favorable safety in clinical use, with laboratory abnormalities comparable to other antibiotics. Most patients experienced no significant issues, indicating good tolerability for treating serious bacterial infections.

    Area of Science:

    • Pharmacology
    • Clinical Microbiology
    • Drug Safety

    Background:

    • Ceftriaxone is a widely used third-generation cephalosporin antibiotic.
    • Assessing the safety profile of antibiotics is crucial for clinical practice.
    • Previous studies have indicated ceftriaxone's efficacy, but comprehensive laboratory safety data is essential.

    Purpose of the Study:

    • To evaluate the safety of ceftriaxone through laboratory test abnormalities in a large patient cohort.
    • To compare the incidence of laboratory abnormalities with other antimicrobial agents.
    • To analyze safety data across different dosing frequencies and patient populations.

    Main Methods:

    • Meta-analysis of 153 clinical studies involving 2,640 patients treated with ceftriaxone.

    Related Experiment Videos

  • Evaluation of laboratory test values, including hematologic, hepatic, and renal parameters.
  • Comparison of adverse event rates between once-daily and twice-daily dosing regimens.
  • Comparative analysis against cephalosporins and other antimicrobial drugs.

    • Main Results:

    • The overall incidence of laboratory test abnormalities was 19.0% during ceftriaxone therapy.
    • Most frequent abnormalities were hematologic (14.4%), hepatic (5.0%), and renal (1.4%).
    • Pediatric patients showed higher rates of hematologic (30.8%) and hepatic (7.7%) abnormalities.
    • Thrombocytosis was more frequent with twice-daily dosing (5.3%) versus once-daily (1.8%).
    • Ceftriaxone's safety profile was comparable to other cephalosporins and comparative drugs.

    Conclusions:

    • Ceftriaxone exhibits an acceptable safety profile in clinical settings.
    • Laboratory test abnormalities are generally infrequent and comparable to alternative antibiotics.
    • The drug is well-tolerated for treating serious bacterial infections, supporting its continued use.